The features discussed in this study (e.g., bulbar weakness, respiratory involvement) are most prominent in Grades IIb-V, with Grade V specifically characterized by respiratory failure due to neuromuscular junction dysfunction.” 80% of MG patients have anti-AChR antibodies, 50% of AChR-seronegative patients have anti-MuSK antibodies, and 20–30% of AChR-positive patients have anti-Titin antibodies, which are key in MG’s development (4, 5). This evidence concerns the gene TTN and myasthenia gravis.